Exendins and exendin analogs for diabetic therapy: a patent review (2012-2015).

Abstract:

INTRODUCTION:Since exendin-4 (exenatide) was approved for diabetes therapy in 2005, several exendin analogs have been developed for the treatment of type 2 diabetes mellitus. As exenatide is a relatively short-acting injectable agent, major approaches have focused on developing long-acting exendin analogs to improve patient compliance and convenience. AREAS COVERED:In this review, the authors report on patents related to exendins and exendin analogs from 2012 to 2015. The patents have been divided into three categories based on the technologies used to develop the new chemical entities: 1) chemical bioconjugate analogs; 2) recombinant fusion protein analogs; and 3) multifunctional peptide analogs. EXPERT OPINION:Recently, research on exendins and their analogs has grown significantly, leading to the development of long-acting analogs and multifunctional peptides. While long-acting injectable agents are still the major products in the pharmaceutical industry, a significant growth is expected in the development of orally available exendins.

journal_name

Expert Opin Ther Pat

authors

Park EJ,Lim SM,Lee KC,Na DH

doi

10.1080/13543776.2016.1192130

subject

Has Abstract

pub_date

2016-07-01 00:00:00

pages

833-42

issue

7

eissn

1354-3776

issn

1744-7674

journal_volume

26

pub_type

杂志文章,评审
  • Solid lipid nanoparticles: a review on recent perspectives and patents.

    abstract::Introduction: Solid lipid nanoparticles (SLNs) are solid core lipid nanocarriers, which can hold both hydrophilic and hydrophobic drugs. They can be made up of biocompatible ingredients and therefore are one of the preferred choices for drug delivery. Surface modifications of SLNs may further provide unique features t...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1080/13543776.2020.1720649

    authors: Paliwal R,Paliwal SR,Kenwat R,Kurmi BD,Sahu MK

    更新日期:2020-03-01 00:00:00

  • Parthenogenetically activated human oocytes and parthenogenetic embryonic stem cells: US20100233143.

    abstract:BACKGROUND:The application (US20100233143) is in the field of embryonic stems cells (ESCs) and the generation of ESCs from parthenogenetically activated human oocytes. OBJECTIVE:It aims at determining optimal conditions for parthenogenetically activating human oocytes. METHODS:Oocytes isolated from female donors were...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543776.2011.581230

    authors: Taupin P

    更新日期:2011-08-01 00:00:00

  • Trace amine associated receptor 1 (TAAR1) modulators: a patent review (2010-present).

    abstract::Introduction: The greater interest in TAAR1-mediated potential for the treatment of different pathologies, especially those related to CNS disorders, has given a considerable boost to the search for developing TAAR1-selective small molecules.Areas covered: During the last decade, the medicinal chemistry efforts have a...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1080/13543776.2020.1708900

    authors: Tonelli M,Cichero E

    更新日期:2020-02-01 00:00:00

  • Inhibitors of the renal outer medullary potassium channel: a patent review.

    abstract:INTRODUCTION:Hypertension represents a substantial cardiovascular risk factor. Among anti-hypertensive drugs, diuretics play an important role. Nevertheless, they present adverse effects such as hypokalemia or hyperkalemia. In this panorama, inhibitors of the renal outer medullary potassium (ROMK) channels are emerging...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543776.2015.1050792

    authors: Martelli A,Testai L,Breschi MC,Calderone V

    更新日期:2015-01-01 00:00:00

  • A novel DP2 receptor antagonist (AM-461): a patent evaluation of WO2011085033.

    abstract::This application claims salts and crystalline forms of a previously disclosed DP2 receptor antagonist (2-[3-[2-(tert-butylsulfanylmethyl)-4-(2,2-dimethylpropanoylamino)phenoxy]-4-methoxy-phenyl]acetic acid (1)). It also claims compositions containing the free acid and its salts, especially the sodium salt and their us...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543776.2011.636738

    authors: Norman P

    更新日期:2011-12-01 00:00:00

  • Pharmaceutical agents for treatment of leishmaniasis: a patent landscape.

    abstract:INTRODUCTION:Leishmaniasis is a neglected tropical disease caused by protozoa of the genus Leishmania. Worldwide, approximately 1.5-2 million new cases of leishmaniasis and 20,000-30,000 deaths occurs each year. Effective treatment for all forms of leishmaniasis have numerous adverse effects contributing to poor adhere...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章

    doi:10.1080/13543776.2020.1789100

    authors: Barbosa Gomes de Carvalho YM,Shanmugam S,Batista MS,Serafini MR,Araújo AAS,Quintans Júnior LJ

    更新日期:2020-08-01 00:00:00

  • 3-Hydroxy-3-methylglutaryl-coenzyme A reductase modulator: toward age- and sex-personalized medicine.

    abstract::Cholesterol homeostasis maintenance is regulated by a cellular feedback system that senses cholesterol amount in cellular membranes. 3-hydroxy 3-methylglutaryl coenzyme A reductase (HMGR) plays a pivotal role in cholesterol metabolism as it is the key rate-limiting enzyme of its biosynthetic pathway; its inhibition pr...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章

    doi:10.1517/13543776.2015.1061996

    authors: Pallottini V

    更新日期:2015-01-01 00:00:00

  • Substituted oxadiazoles: a patent review (2010 - 2012).

    abstract:INTRODUCTION:The oxadiazoles represent a class of five-membered heterocyclic compounds which are of considerable interest in different areas of medicinal chemistry and drug discovery. Oxadiazoles can exist in different regioisomeric forms and employ in various agents with a broad range of biological activities. This re...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543776.2013.797409

    authors: Zarghi A,Hajimahdi Z

    更新日期:2013-09-01 00:00:00

  • Signal transducer and activator of transcription 3 inhibitors: a patent review.

    abstract:IMPORTANCE OF THE FIELD:Aberrant activation of signal transducer and activator of transcription (Stat) 3, a member of the STAT family of proteins, is prevalent in numerous human cancers and is now widely recognized as a critical molecular abnormality and a master regulator of tumor processes. Thus, the identification o...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543776.2011.539205

    authors: Page BD,Ball DP,Gunning PT

    更新日期:2011-01-01 00:00:00

  • Small molecule DNA-PK inhibitors as potential cancer therapy: a patent review (2010-present).

    abstract::Introduction: DNA-dependent protein kinase (DNA-PK) plays a crucial role in the repair of DSBs via non-homologous end joining (NHEJ). Several DNA-PK inhibitors are being investigated for potential anticancer treatment in clinical trials. Area covered: This review aims to give an overview of patents published since 201...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章

    doi:10.1080/13543776.2021.1866540

    authors: Hu S,Hui Z,Lirussi F,Garrido C,Ye XY,Xie T

    更新日期:2020-12-21 00:00:00

  • Natural, synthetic and semisynthetic glycolipid inhibitors of glioma growth.

    abstract::Neurostatin, a natural glycosphingolipid inhibitor of astroblast and astrocytoma division, present in mammalian brain, is the modified ganglioside O-acetylated GD1b. It is cytostatic for rat astroblasts, C6 glioma cells and various human astrocytoma lines grades III and IV, with median inhibitory dose values ranging 1...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章

    doi:10.1517/13543776.14.4.487

    authors: Nieto-Sampedro M,Doncel-Pérez E,Fernández-Mayoralas A

    更新日期:2004-04-01 00:00:00

  • Xanthine oxidase inhibitors: patent landscape and clinical development (2015-2020).

    abstract:INTRODUCTION:Xanthine oxidase (XO) is a molybdoflavoprotein that catalyzes the oxidative hydroxylation of purines to produce uric acid and reactive oxygen species. These reaction products can cause severe disease conditions like hyperuricemia which makes XO enzyme, an important therapeutic target in diseases like gout....

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章

    doi:10.1080/13543776.2020.1811233

    authors: Singh JV,Bedi PMS,Singh H,Sharma S

    更新日期:2020-10-01 00:00:00

  • VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).

    abstract:INTRODUCTION:Angiogenesis is an important component of certain normal physiological processes, but aberrant angiogenesis contributes to some pathological disorders and in particular to tumor growth. Activation of vascular endothelial growth factor receptor-2 (VEGFR-2) by vascular endothelial growth factor (VEGF) is a c...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1080/13543776.2017.1344215

    authors: Peng FW,Liu DK,Zhang QW,Xu YG,Shi L

    更新日期:2017-09-01 00:00:00

  • Therapeutic applications of the gaseous mediators carbon monoxide and hydrogen sulfide.

    abstract:BACKGROUND:Hydrogen sulfide (H(2)S) and carbon monoxide (CO) are endogenously produced gaseous autacoids that regulate a number of physiological processes, including the inflammatory response, cell death and proliferation, neural transmission and smooth muscle tone. OBJECTIVE/METHODS:The current review aims to provide...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543770902858824

    authors: Bannenberg GL,Vieira HL

    更新日期:2009-05-01 00:00:00

  • Lessons from black pepper: piperine and derivatives thereof.

    abstract:INTRODUCTION:Piperine is a simple and pungent alkaloid found in the seeds of black pepper (Piper nigrum). Following its isolation and full characterization, the biological properties of piperine have been extensively studied, and piperine-like derivatives have shown an interesting range of pharmacological activities. I...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543776.2016.1118057

    authors: Chavarria D,Silva T,Magalhães e Silva D,Remião F,Borges F

    更新日期:2016-01-01 00:00:00

  • Benzoxaborole compounds for therapeutic uses: a patent review (2010- 2018).

    abstract:INTRODUCTION:Benzoxaborole is a versatile boron-heterocyclic scaffold which has found in the last 10 years a broad spectrum of applications in medicinal chemistry, due to its physicochemical and drug-like properties. Use of benzoxaborole moiety in the design of compounds led to the discovery of new classes of anti-bact...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1080/13543776.2018.1473379

    authors: Nocentini A,Supuran CT,Winum JY

    更新日期:2018-06-01 00:00:00

  • Novel glucokinase activators: a patent review (2008 - 2010).

    abstract:IMPORTANCE OF THE FIELD:Small molecule glucokinase activators (GKAs) continue to represent a potential strategy to treat type 2 diabetes (T2D). Glucokinase (GK) primarily exerts its effect through modulatory actions in pancreatic β-cells and hepatocytes. It couples insulin secretion in the pancreas with plasma glucose ...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543776.2011.542413

    authors: Sarabu R,Berthel SJ,Kester RF,Tilley JW

    更新日期:2011-01-01 00:00:00

  • Bitopic muscarinic agonists and antagonists and uses thereof: a patent evaluation of US20160136145A1.

    abstract:INTRODUCTION:Bitopic M ligands, that is, ligands that interact both with the ortho- and allosteric binding sites of the M receptor subtypes, hold great potential as novel selective for muscarinic acetylcholine (M) ligands for several therapeutic applications. Areas covered: The patent application describes a set of com...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章

    doi:10.1080/13543776.2017.1272577

    authors: Holzgrabe U,Decker M

    更新日期:2017-02-01 00:00:00

  • Human neural progenitor and stem cells: US20080107633A1.

    abstract:BACKGROUND:The application is in the field of neural stem cells (NSCs) and cellular therapy. OBJECTIVE:It aims at establishing conditions for the isolation and propagation of neural progenitor and stem cells from human fetal tissue, with high rate of growth and high yields of differentiation into the neuronal, astrogl...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章

    doi:10.1517/13543770802688909

    authors: Taupin P

    更新日期:2009-03-01 00:00:00

  • Developments in inhaled combination therapies: patent activity 2013-2014.

    abstract:INTRODUCTION:Since the 1970s, the treatment options for asthma and chronic obstructive pulmonary disease have increasingly relied upon the use of inhaled drug formulations, generally from handheld inhaler devices. The introduction of combinations of a corticosteroid with a long-acting β2 agonist has dramatically transf...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543776.2015.1064394

    authors: Norman P

    更新日期:2015-01-01 00:00:00

  • Dipeptidyl peptidase IV inhibitors as a potential target for diabetes: patent review (2015-2018).

    abstract:INTRODUCTION:Dipeptidyl peptidase 4 (DPP-4) belongs to the family of serine proteases and is involved in the degradation of GLP-1 and GIP hormones, which enhance the production and release of insulin. Targeting DPP-4 inhibitors is increasingly being considered as promising paradigms to treat type 2 diabetes mellitus an...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1080/13543776.2019.1632290

    authors: Hussain H,Abbas G,Green IR,Ali I

    更新日期:2019-07-01 00:00:00

  • An update on liposomes in drug delivery: a patent review (2014-2018).

    abstract::Introduction: Pharmacotherapy is limited by the inefficient drug targeting of non-healthy cells/tissues. In this pharmacological landscape, liposomes are contributing to the impulse given by Nanotechnology to optimize drug therapy. Areas covered: The analysis of the state-of-the-art in liposomal formulations for drug ...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1080/13543776.2019.1679767

    authors: El-Hammadi MM,Arias JL

    更新日期:2019-11-01 00:00:00

  • Acylhydrazone derivatives: a patent review.

    abstract:INTRODUCTION:The N-acylhydrazone (NAH) moiety has been characterized as a privileged structure, capable of providing ligands points for more than one type of bioreceptor. Modifications of the subunits bonded to its acyl and imine functions resulted in several derivatives, which modulate a great diversity of molecular t...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543776.2014.959491

    authors: Maia Rdo C,Tesch R,Fraga CA

    更新日期:2014-11-01 00:00:00

  • Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.

    abstract::In recent years, the involvement of the Hedgehog (Hh) signaling pathway in various human diseases and dysfunctions has been clearly demonstrated. Smoothened (Smo), one of the upstream signal transducers, has been the most druggable target of the Hh pathway. However, the emergence of resistance to Smo inhibitors and th...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章

    doi:10.1517/13543776.2016.1132309

    authors: Manetti F,Petricci E

    更新日期:2016-01-01 00:00:00

  • A patent review of discoidin domain receptor 1 (DDR1) modulators (2014-present).

    abstract::Introduction: Discoidin domain receptor 1 (DDR1) is a collagen-activated receptor tyrosine kinase. Upon collagen binding, DDR1 undergoes tyrosine autophosphorylation, which consequently triggers downstream genetic and cellular pathways and plays critical roles in the regulation of cellular morphogenesis, differentiati...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1080/13543776.2020.1732925

    authors: Guo J,Zhang Z,Ding K

    更新日期:2020-05-01 00:00:00

  • Small molecule c-Met kinase inhibitors: a review of recent patents.

    abstract:IMPORTANCE OF THE FIELD:c-Met kinase is the receptor for hepatocyte growth factor. Primarily expressed on epithelial and mesenchymal cells its normal function is associated with wound healing, liver regeneration and embryo development. However, dysregulation of c-Met through overexpression, gene amplification, mutation...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543770903514137

    authors: Porter J

    更新日期:2010-02-01 00:00:00

  • Therapeutic uses of melatonin and melatonin derivatives: a patent review (2012 - 2014).

    abstract:INTRODUCTION:Melatonin is a neurohormone involved in the regulation of circadian rhythms, with potent antioxidant activity. It has a wide functional repertoire, with effects almost on all tissues and organs. It is mainly used as a dietary supplement for sleep regulation and re-synchronization of disrupted circadian rhy...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543776.2014.1001739

    authors: Rivara S,Pala D,Bedini A,Spadoni G

    更新日期:2015-04-01 00:00:00

  • QSAR modelling: a therapeutic patent review 2010-present.

    abstract:INTRODUCTION:Quantitative Structure-Activity Relationship (QSAR) models are becoming one of the most interesting fields for developing therapeutics and therapeutics related patents. At present, QSAR methodologies comprise a series of possibilities, including joining forces with machine learning methods and increasing e...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1080/13543776.2018.1475560

    authors: Halder AK,Moura AS,Cordeiro MNDS

    更新日期:2018-06-01 00:00:00

  • Tryptase inhibitors: a patent review.

    abstract:INTRODUCTION:Tryptase is one of the main serine-proteinases located in the secretory granules of mast cells, and is released through degranulation, which is involved in the pathogenesis of allergic inflammatory disease, cardiovascular diseases, lung fibrosis and tumor. Therefore, inhibitors targeting tryptase may repre...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1080/13543776.2017.1322064

    authors: Ni WW,Cao MD,Huang W,Meng L,Wei JF

    更新日期:2017-08-01 00:00:00

  • Aminothienopyridazines as imaging probes of tau pathology: a patent evaluation of WO2013090497.

    abstract::Small-molecule ligands, amenable to positron emission tomography (PET) imaging of different types of neurodegenerative disease-associated amyloid deposits in the CNS of living patients, hold considerable promise for diagnostic purposes, as well as for monitoring disease progression and the effectiveness of treatments....

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章

    doi:10.1517/13543776.2014.871526

    authors: Ballatore C,Smith AB 3rd,Lee VM,Trojanowski JQ,Brunden KR

    更新日期:2014-03-01 00:00:00